Struggling DNA testing firm 23andMe to be bought for $256m
Published: 5/19/2025

DNA testing firm 23andMe to be acquired by Regeneron Pharmaceuticals for $256 million, preserving user privacy while enhancing drug development. 23andMe has struggled following bankruptcy filing, data breach, and failed business model pivots. Regeneron to absorb assets, maintaining 23andMe as a wholly-owned unit for genetic research.